Incubating Hep G2 cells for 18 h with triparanol, buthiobate and low concentrations (< 0.5 /uM) of U18666A, inhibitors of desmosterol A24-reductase, of lanosterol l4x-demethylase and of squalene-2,3-epoxide cyclase (EC 5.4.99.7) respectively, resulted in a decrease of the HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase activity. However, U18666A at concentrations higher than 3/tM increased the HMG-CoA reductase activity in a concentration-dependent manner. None of these inhibitors influenced directly the reductase activity in Hep G2 cell homogenates. Analysis by t.l.c. of 14C-labelled non-saponifiable lipids formed from either [14C]acetate or [14C]mevalonate during the cell incubations confirmed the sites of action of the drugs used. Beside the 14C-labelled substrates of the blocked enzymes and 14C-labelled cholesterol, another non-saponifiable lipid fraction was observed, which behaves as polar sterols on t.l.c. This was the case with triparanol and at those concentrations of U18666A that decreased the reductase activity, suggesting that polar sterols may play a role in suppressing the reductase activity.
INTRODUCTION
The human hepatoma cell line Hep G2 seems to be a good model for the study of the regulation of HMG-CoA reductase (EC 1.1.1.34), the rate-limiting enzyme in cholesterol biosynthesis (Rodwell et al., 1976) , in human hepatocytes (Cohen et al., 1984 . It was shown that in Hep G2 cells compactin, an inhibitor of the reductase itself (Endo et al., 1976) , gave an induction of the reductase activity (measured after removal of the drug; Cohen et al., 1984) . This induction could be partially prevented by LDL, and the remaining activity was abolished by simultaneous addition of mevalonate . The same observation was made in other cell types (Brown & Goldstein, 1980; Cohen et al., 1982) . These findings suggest the existence of at least two classes of mevalonate-derived effectors involved in the regulation of HMG-CoA reductase activity, i.e. effectors compensated by LDL uptake (possibly sterol effectors) and effectors not introduced into the cell by LDL (possibly non-sterol effectors) (Brown & Goldstein, 1980; Cohen et al., 1982 Cohen et al., , 1985 . In order to gain more insight into the nature of these effectors, we investigated the effect of several inhibitors of the cholesterolbiosynthetic pathway on the reductase activity. The accumulation of intermediates before the site of inhibition, and/or the depletion of metabolites behind the blockade, may influence the HMG-CoA reductase activity. In the experiments described here we used U 18666A {3,f-[2-(diethylamino)ethoxy]androst-5-en-1 7-one} as an inhibitor of squalene-2,3-epoxide cyclase (EC 5.4.99.7) (Sexton et al., 1983) . The use of buthiobate (S-n-butyl S'-p-t-butylbenzyl N-3-pyridyldithiocarbonimidate) in mammalian cell-culture studies was not previously reported. It was found to block lanosterol 14a-demethylase in yeast cells (Kato & Kawase, 1976; Aoyama et al., 1983) and in rat liver microsomal preparations (Yoshida & Aoyama, 1985) . Triparanol { 1 - [p-(,8-diethylaminoethoxy) phenyl]-1 -(p-tolyl)-2-(pchlorophenyl)ethanol} was used as an inhibitor of desmosterol A24-reductase (Avigan et al., 1960; Gibbons & Pullinger, 1977 (Chen, 1967) and loaded with palmitate (Fluka A. G.; 10 mol of palmitate/g of albumin; Spector & Hoak, 1969) . Instafluor and Picofluor were from United Packard Industries. LDL (density 1.03-1.05 g/ml) was isolated from freshly collected pooled blood by density-gradient ultracentrifugation (Redgrave et al., 1975) . All other chemicals were of analytical grade. Human hepatoma cell line Hep G2 The cells were cultured in 10 cm2 multiwell dishes in DMEM, supplemented with 10% (w/v) foetal bovine serum (Havekes et al., 1983) . At 18 h before harvesting, the medium was replaced with DMEM, supplemented with 10% (w/v) palmitate-loaded albumin and the different inhibitors at concentrations as indicated in the Results section. The final concentrations of the solvents of the different inhibitors were: 0.015-0.1 % ethanol for U18666A, 0.2% dimethyl sulphoxide for buthiobate, 2% propane-1,2-diol for triparanol, and 0.12% ethanol in experiments with compactin. At these concentrations the solvents did not show a significant effect on the HMG-CoA reductase activity. HMG-CoA reductase assay HMG-CoA reductase activity was determined in the cell homogenate as described previously (Cohen et al., 1984) . Values were obtained from duplicate determinations in two homogenates of identically treated cells. The average values for the individual homogenates agreed within 10%. Protein concentrations were determined in the cell homogenate as described by Lowry et al. (1951) (Lowry et al., 1951) . Thereafter, total lipids were extracted from cell homogenate and medium together, as described by Bligh & Dyer (1959) (1979) . The plates were developed twice in acetonitrile/ chloroform (2:1, v/v). Cholesterol (RF 0.44), desmosterol (RF 0.51) and lanosterol (RF 0.61) were used as standards.
Standards run in separate lanes were detected by heating after spraying with H2SO4. After spraying with En3hance, the "4C-labelled non-saponifiable lipids were detected by fluorography.
The "4C-labelled non-saponifiable lipids from control cells (incubated without inhibitor) migrated in only one spot, corresponding to cholesterol in both t.l.c. systems. Radioactively labelled spots were scraped into scintillation vials containing 0.5 ml of methanol and counted for radioactivity after addition of 10 ml of Instafluor. Blocking cholesterol biosynthesis at the desmosterol A24-reductase site by triparanol decreases the reductase activity in Hep G2 cells. Fig. 1(a) shows the HMG-CoA reductase activity as determined in the cell homogenate after incubation of the cells for 18 h at 37 'C with medium supplemented with the indicated triparanol concentration. The reductase activity was suppressed in a concentration-dependent manner finally to 200% of the control value at 20 /M drug. Triparanol had no effect on the reductase activity in the cell homogenate (result not shown). In order to confirm the site of action of triparanol, the accumulation of lipid intermediates of the pathway to cholesterol was determined. This was performed by determination of [14C]mevalonate incorporation into non-saponifiable lipids, extracted from cells incubated for 18 h with the different triparanol concentrations indicated in (Sexton et al., 1983) . As depicted in Fig. l(b (Fig. 2a) . At 10 ,uM-buthiobate the enzyme activity was about half the control value. Buthiobate had no effect on the reductase activity in the cell homogenate (results not shown). Fig. 2(b) shows the results of the incorporation of [14C]mevalonate into non-saponifiable lipids in cells incubated with the indicated buthiobate concentrations. Separation by means of t.l.c. system I indicated that only 14C-labelled cholesterol and lanosterol were detectable in the lipid extracts. As shown in Fig. 2(b) , buthiobate caused a concentration-dependent decrease in the labelling of cholesterol, which led to an almost complete abolition of this incorporation at 10 /M drug. On the other hand, the incorporation of label into lanosterol strongly increased at the concentrations tested. This observation confirms the inhibitory effect of buthiobate on lanosterol 14a-demethylase in Hep G2 cells. Effect of U18666A on HMG-CoA reductase activity and on 14Clacetate incorporation into non-saponifiable lipids
The squalene-2,3-epoxide cyclase inhibitor U18666A was used to investigate whether a decrease in sterologenesis and the subsequent accumulation of non-sterols has an effect on the reductase activity in Hep G2 cells. HMG-CoA reductase activity was determined after incubation of the cells for 18 h with medium containing different concentrations of U18666A. The results are depicted in Fig. 3(a) . At low U I 8666A concentrations the reductase activity was concentration-dependently sup- (a) pressed, with a minimum (40% of control activity) around 0.5 /M. However, at higher concentrations (> 3 /M) the enzyme activity was stimulated ( Fig. 3a; cf. also Table 1 and Fig. 4 Fig. 3(b) (Cohen et al., 1984 . Analogous to this observation, it was investigated whether LDL had the same effect on the U 18666A-induced increase in the reductase activity, supposing that LDL influx could compensate for a missing sterol regulator.
In Table 1 into effectors compensatable by LDL (possibly sterol effectors) and non-LDL-related (possibly non-sterol) effectors. With the aid of U 18666A, which blocks sterologenesis (see, e.g., Fig. 3b ; 92% inhibition at 10 1zM-U186666A), we are able to discriminate more clearly between sterol and non-sterol effectors. Therefore we investigated the effect of blocking sterologenesis with 30 ,iM-U18666A, combined with the additional effects of compactin and mevalonate. The results are shown in Fig.  4 . Mevalonate decreased the reductase activity relatively much more in compactin-treated cells (Fig. 4 ; cf. bars b and e) than in U1 8666A-treated cells (Fig. 4 ; cf. bars c and f). The additional increase in activity in U18666A-treated cells caused by compactin (Fig. 4 ; cf. bars c and d) could almost totally be prevented by addition of mevalonate (Fig. 4, bar g ). From these experiments it was concluded that, in total blockade of sterologenesis by U1 8666A, mevalonate or mevalonate-derived products still influenced the reductase activity, indicating the existence of a non-sterol effector.
DISCUSSION
It was shown that, in the human hepatoma cell line Hep G2, the drugs triparanol, buthiobate and U1 8666A were strong inhibitors of cholesterol biosynthesis (Figs. lb, 2b and 3b respectively). The blockade at the desmosterol reductase site by triparanol resulted in a decrease in HMG-CoA reductase activity (Fig. 1) . The opposite effect, i.e. reductase stimulation by triparanol, was observed by Havel et al. (1979) . However, in that case, with a primary rat hepatocyte culture and a high concentration of triparanol (30 /M), the drug treatment resulted in a strong inhibition of squalene-2,3-epoxide cyclase. Their findings are in agreement with our observations with high concentrations of U 18666A (Fig.  3) , indicating that blockage of sterol formation caused an increase in HMG-CoA reductase activity, confirming the existence of a sterol effector.
In treating Hep G2 cells with triparanol, we observed the formation of polar sterols. It is not likely that these sterols are formed from the accumulated ['4C]desmosterol during the extraction procedure, because of the large quantity of carrier desmosterol added. Although the nature of these polar sterols is not yet known, the possibility exists that they are involved in decreasing the reductase activity. It was shown that certain polar sterols (oxysterols) act as potent inhibitors of the reductase activity (Kandutsch et al., 1978; Schroepfer, 1981) . Although we cannot exclude that in this case the accumulation of desmosterol might have contributed to the decrease in reductase activity, limited desmosterol accumulation in rat hepatocytes (induced by a short incubation with triparanol) had no effect on the rate of C27 sterol synthesis (Gibbons & Pullinger, 1977; Pullinger & Gibbons, 1983 (Fig. 2) . Besides cholesterol, the only accumulating sterol detected was lanosterol, suggesting that this sterol may be involved in the decrease in reductase activity. On the one hand, the observed relationship between the accumulation of methyl sterols and the decrease in HMG-CoA reductase activity in primary rat hepatocyte culture cells (Havel et al., 1979) and the inhibition of the reductase by lanosterol in human fibroblasts (Brown & Goldstein, 1974) seem to support this suggestion. However, on the other hand it was reported more recently (Gupta et al., 1986 ) that lanosterol accumulation in rat intestinal epithelial cells (caused by inhibition of lanosterol 14a-demethylase with the drug ketoconazole) was not accompanied by a decrease in reductase activity at drug concentrations higher than 15 liM. On the contrary, a stimulation of enzyme activity was observed, which was found to correlate with a decrease in polar sterol formation. Although not detected in the t.l.c. system used, we cannot exclude the formation of very minor amounts of other, possibly inhibitory, sterols in the cells treated with buthiobate.
The effect of incubating Hep G2 cells with the lanosterol 14a-demethylase inhibitor ketoconazole (Kempen & Cohen, 1985) Gupta et al. (1986) . Polar sterols were also detected in the non-saponifiable lipid extracts from the Hep G2 cells treated with low concentrations of U 18666A, whereas squalene-2,3-epoxide cyclase was partially blocked (accumulation of the squalene epoxides and cholesterol still formed) and reductase activity was decreased (Fig. 3) . At high concentrations of U18666A, when the squalene 2,3-epoxide cyclase was blocked almost completely, the formation of polar sterols was much decreased, accompanied by a strong stimulation of the reductase activity. Again, these results suggest that polar sterols are involved in the suppression of the reductase activity. Similar observations were made by Panini et al. (1984) , by incubating rat intestinal epithelial cells with U1 8666A. They concluded that when squalene epoxide cyclase is partially blocked, the diepoxide, formed from squalene epoxide, but not an intermediate of cholesterol biosynthesis, is converted into polar 24,25-epoxide sterols, which inhibit the reductase activity. When the cyclase is blocked completely, this conversion does not take place and the inhibition of the reductase activity is subsequently abolished. They did not report a strong stimu-lation of the reductase activity at high U 18666A concentrations, as was observed in the experiments described here.
LDL enhanced the stimulating effect of U18666A on HMG-CoA reductase activity at high drug concentrations. Thus LDL could not replace the deficit of sterols caused by the blockade of sterologenesis, as effector in the inhibition of the reductase activity. The decrease in reductase activity caused by LDL alone was not accompanied by a detectable accumulation of 14C-labelled polar sterols (Fig. 3c) . This contradicts Panini et al. (1984) , who observed an abolition of the LDLinduced inhibition of the reductase activity by U 18666A and suggested that LDL should influence the squalene 2,3-epoxide cyclase in the same way as low concentrations of U 18666A. No preferential binding of U 18666A to LDL was detected, making an enhanced influx of U18666A by LDL unlikely (results not shown). The cholesterol content ofcells incubated with LDL increased markedly, but this was independent of the Ut 8666A concentration, indicating that the LDL influx was not impaired by the drug. The possibility remains that the LDL effector is derived from the cholesterol introduced, but that its synthesis is blocked by U18666A. The exact mechanism is as yet unclear.
When mevalonate was added to Hep G2 cells together with Ut 8666A in a sterologenesis preventing concentration, the Ut 8666A-induced elevation of the reductase activity could not be abolished. However, when mevalonate was added to Hep G2 cells in the presence of the same concentration ofU 18666A and 2 ,tM-compactin, the additional increase in reductase activity caused by compactin could be prevented by mevalonate (Fig. 4) .
